Is monotherapy withβ-lactam antibiotics still up to date? New aspects for treatment of severe infections;Sind Monotherapien mit β-Laktamantibiotika noch zeitgemäβ?

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 6, 2012, Pages 267-270

  Heizmann, P ^a   Lode, H ^b   Heizmann, W R ^c  

^a Petra Heizmann Innere Medizin   (Germany)

^b Inst fur Klinische Pharmakologie   (Germany)

^c Diagnostik München   (Germany)

Author keywords

bactericidal; bacteriostatic; combination therapy; sepsis; virulence

Indexed keywords

BETA LACTAM ANTIBIOTIC;

ANTIBIOTIC THERAPY; DISEASE SEVERITY; INFECTION; MONOTHERAPY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMS; CELL WALL; CRITICAL CARE; CROSS INFECTION; DRUG THERAPY, COMBINATION; EXOTOXINS; GUIDELINE ADHERENCE; HUMANS; IMMUNIZATION; INTERLEUKIN-8; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 84856557921     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1298878     Document Type: Review

References (40)

1. Azuma K, Koike K, Kobayashi T et al. Detection of circulating superantigens in an intensive care unit population. Int J Infect Dis: 2004; 8 292 298 (Pubitemid 39119853)
2. Becker K, Friedrich AW, Lubritz G et al. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol: 2003; 41 1434 1439 (Pubitemid 36428085)
3. Bernardo K, Pakulat N, Fleer S et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother: 2004; 48 546 555 (Pubitemid 38141715)
4. Bttcher T, Ren H, Goiny M et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem: 2004; 91 1450 1460 (Pubitemid 39658571)
5. Bubeck Wardenburg J, Bae T, Otto M et al. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med: 2007; 13 1405 1406 (Pubitemid 350224232)
6. Buijs J, Dofferhoff AS, Mouton JW et al. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. J Antimicrob Chemother: 2007; 59 926 933 (Pubitemid 47073364)
7. Burillo A, Gil Y, Lpez-Fabal F et al. Can tigecycline rescue the activity of imipenem against highly resistant metallo-lactamase-nonproducing Pseudomonas aeruginosa? ECCMID: 2009; P1589
8. Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: A systematic review. J Infection: 2011; 63 187 199
9. Dauwalder O, Thomas D, Ferry T et al. Comparative inflammatory properties of staphylococcal superantigenic enterotoxins SEA and SEG: implications for septic shock. J Leukoc Biol: 2006; 80 753 758 (Pubitemid 44835893)
10. Eckmann C, Heizmann WR, Leitner E et al. Prospective, non interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections new insights in clinical results and treatment practice. Chemotherapy: 2011; 57 275 284
11. Engel C, Brunkhorst FM, Bone HG et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med: 2007; 33 606 618 (Pubitemid 46474888)
12. Ferry T, Thomas D, Genestier AL et al. Comparative prevalence of superantigen genes in Staphylococcus aureus isolates causing sepsis with and without septic shock. Clin Infect Dis: 2005; 41 771 777 (Pubitemid 41266740)
13. Gemmell CG, Ford CW. Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother: 2002; 50 665 672 (Pubitemid 35331683)
14. Gerber J, Pohl K, Sander V et al. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother: 2003; 47 1313 1317 (Pubitemid 36368591)
15. Hffken G, Lorenz J, Kern W et al. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany. Pneumologie: 2009; 63 e1 68
16. Hoffmann N, Lee B, Hentzer M et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother: 2007; 51 3677 3687 (Pubitemid 47519359)
17. Jaksic B, Martinelli G, Perez-Oteyza J et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis: 2006; 42 597 607 (Pubitemid 43271371)
18. Jang HC, Kim SH, Kim KH et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis: 2009; 49 395 401
19. Kaneko J, Kimura T, Narita S et al. Complete nucleotide sequence and molecular characterization of the temperate staphylococcal bacteriophage phiPVL carrying Panton-Valentine leukocidin genes. Gene: 1998; 215 57 67 (Pubitemid 28359218)
20. Khan AA, Priya S, Saha B. IL-2 regulates SEB induced toxic shock syndrome in BALB/c mice. PLoS One: 2009; 4 e8473
21. Kishi K, Hirai K, Hiramatsu K et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother: 1999; 43 616 622 (Pubitemid 29109528)
22. Kunkel M, Chastre JE, Kollef M et al. Linezolid vs Vancomycin In the Treatment of Nosocomial Pneumonia Proven Due to Methicillin-Resistant Staphylococcus aureus. IDSA 48th Annual Meeting: 2010; Abstract 5047
23. Levy MM, Dellinger RP, Townsend SR et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med: 2010; 36 222 231
24. Liu JW, Lee IK, Tang HJ et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med: 2006; 166 2117 2123
25. Lotz S, Starke A, Ziemann C et al. Beta-lactam antibiotic-induced release of lipoteichoic acid from Staphylococcus aureus leads to activation of neutrophil granulocytes. Ann Clin Microbiol Antimicrob: 2006; 5 15
26. Martin-Loeches I, Lisboa T, Rodriguez A et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med: 2010; 36 612 620
27. McElroy MC, Harty HR, Hosford GE et al. Alpha-toxin damages the air-blood barrier of the lung in a rat model of Staphylococcus aureus-induced pneumonia. Infect Immun: 1999; 67 5541 5544 (Pubitemid 29455343)
28. Micek ST, Lloyd AE, Ritchie DJ et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother: 2005; 49 1306 1131
29. Pichereau S, Moran JJ, Hayney MS et al. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J Antimicrob Chemother: 2012; 67 123 129
30. Pichereau S, Pantrangi M, Couet W et al. Simulated antibiotic exposures in an in vitro hollow fiber infection model influence toxin gene expression and production in community-associated MRSA strain MW2. Antimicrob Agents Chemother: 2012; 56 140 147
31. Reinhart K, Brunkhorst FM, Bone HG et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci: 2010; 8 Doc14, doi 10.3205/000103
32. Schaad UB, Lips U, Gnehm HE et al. Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. Lancet: 1993; 342 457 461 (Pubitemid 23240309)
33. Shibl AM, Al-Sowaygh IA. Antibiotic inhibition of protease production by Pseudomonas aeruginosa. J Med Microbiol: 1980; 13 345 348
34. Stevens DL, Wallace RJ, Hamilton SM et al. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis: 2006; 42 729 730 (Pubitemid 43271393)
35. Stevens DL, Ma Y, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis: 2007; 195 202 211 (Pubitemid 46080052)
36. Swoboda S, Ober M, Hainer C et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother: 2008; 61 729 733 (Pubitemid 351321153)
37. Tang HJ, Ko WC, Chuang YC et al. Cefazolin plus minocycline against a clinical isolate of Vibrio vulnificus: in vitro and animal studies. Jpn J Infect Dis: 2010; 63 16 18
38. van Langevelde P, van Dissel JT, Ravensbergen E et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother: 1998; 42 3073 3078 (Pubitemid 28553720)
39. van Langevelde P, Ravensbergen E, Grashoff P et al. Antibiotic-induced cell wall fragments of Staphylococcus aureus increase endothelial chemokine secretion and adhesiveness for granulocytes. Antimicrob Agents Chemother: 1999; 43 2984 2989
40. Yanagihara K, Kihara R, Araki N et al. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection. Int J Antimicrob Agents: 2009; 34 477 478